{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Aptevo Therapeutics Inc."},"Symbol":{"label":"Symbol","value":"APVO"},"Address":{"label":"Address","value":"2401 4TH AVENUE SUITE 1050, SEATTLE, Washington, 98121, United States"},"Phone":{"label":"Phone","value":"+1 206 838-0500"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells."},"CompanyUrl":{"label":"Company Url","value":"https://www.aptevotherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Marvin L. White","title":"President, Chief Executive Officer &amp; Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}